Sildenafil inhibits the growth of human colorectal cancer in vitro and in vivo

American Journal of Cancer Research

Volumn 5, Issue 11, 2015, Pages 3311-3324

  Mei, Xiao Long ^a   Yang, Yang ^a   Zhang, Yao Jun ^b   Li, Yong ^c   Zhao, Jin Ming ^b   Qiu, Jian Ge ^a   Zhang, Wen Ji ^a   Jiang, Qi Wei ^a   Xue, You Qiu ^a   Zheng, Di Wei ^a   Chen, Yao ^a   Qin, Wu Ming ^a   Wei, Meng Ning ^a   Shi, Zhi ^a  

^a JINAN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c GUANGDONG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

Colorectal cancer; PDE5; PKG; Sildenafil

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLINE; KT 5823; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; REACTIVE OXYGEN METABOLITE; SILDENAFIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL CYCLE ARREST; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; HCT116 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; SW480 CELL LINE;

EID: 85006216380     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Siegel R, Ma J, Zou Z and Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Cunningham D, Atkin W, Lenz HJ, Lynch HT, Minsky B, Nordlinger B and Starling N. Colorectal cancer. Lancet 2010; 375: 1030-1047.
3. Siegel R, Desantis C and Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014; 64: 104-117.
4. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH and Gingell C. Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8: 47-52.
5. Carson CC and Lue TF. Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 2005; 96: 257-280.
6. Bender AT and Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006; 58: 488-520.
7. Karami-Tehrani F, Moeinifard M, Aghaei M and Atri M. Evaluation of PDE5 and PDE9 expression in benign and malignant breast tumors. Arch Med Res 2012; 43: 470-475.
8. Eggen T, Sager G, Berg T, Nergaard B, Moe BT and Orbo A. Increased gene expression of the ABCC5 transporter without distinct changes in the expression of PDE5 in human cervical cancer cells during growth. Anticancer Res 2012; 32: 3055-3061.
9. Zhang X, Yan G, Ji J, Wu J, Sun X, Shen J, Jiang H and Wang H. PDE5 inhibitor promotes melanin synthesis through the PKG pathway in B16 melanoma cells. J Cell Biochem 2012; 113: 2738-2743.
10. Zhu B and Strada SJ. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem 2007; 7: 437-454.
11. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, Binet JL, Delic J and Merle-Beral H. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003; 101: 265-269.
12. Tinsley HN, Gary BD, Keeton AB, Zhang W, Abadi AH, Reynolds RC and Piazza GA. Sulindac sulfide selectively inhibits growth and induces apoptosis of human breast tumor cells by phosphodiesterase 5 inhibition, elevation of cyclic GMP, and activation of protein kinase G. Mol Cancer Ther 2009; 8: 3331-3340.
13. Zhu B, Vemavarapu L, Thompson WJ and Strada SJ. Suppression of cyclic GMP-specific phosphodiesterase 5 promotes apoptosis and inhibits growth in HT29 cells. J Cell Biochem 2005; 94: 336-350.
14. Whitehead CM, Earle KA, Fetter J, Xu S, Hartman T, Chan DC, Zhao TL, Piazza G, Klein-Szanto AJ, Pamukcu R, Alila H, Bunn PA Jr and Thompson WJ. Exisulind-induced apoptosis in a non-small cell lung cancer orthotopic lung tumor model augments docetaxel treatment and contributes to increased survival. Mol Cancer Ther 2003; 2: 479-488.
15. Piazza GA, Thompson WJ, Pamukcu R, Alila HW, Whitehead CM, Liu L, Fetter JR, Gresh WE Jr, Klein-Szanto AJ, Farnell DR, Eto I and Grubbs CJ. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001; 61: 3961-3968.
16. Thompson WJ, Piazza GA, Li H, Liu L, Fetter J, Zhu B, Sperl G, Ahnen D and Pamukcu R. Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activa tion, and attenuated beta-catenin. Cancer Res 2000; 60: 3338-3342.
17. Whitt JD, Li N, Tinsley HN, Chen X, Zhang W, Li Y, Gary BD, Keeton AB, Xi Y, Abadi AH, Grizzle WE and Piazza GA. A novel sulindac derivative that potently suppresses colon tumor cell growth by inhibiting cGMP phosphodiesterase and beta-catenin transcriptional activity. Cancer Prev Res (Phila) 2012; 5: 822-833.
18. Tinsley HN, Gary BD, Keeton AB, Lu W, Li Y and Piazza GA. Inhibition of PDE5 by sulindac sulfide selectively induces apoptosis and attenuates oncogenic Wnt/beta-catenin-mediated transcription in human breast tumor cells. Cancer Prev Res (Phila) 2011; 4: 1275-1284.
19. Mohamed HA, Girgis NM, Wilcken R, Bauer MR, Tinsley HN, Gary BD, Piazza GA, Boeckler FM and Abadi AH. Synthesis and molecular modeling of novel tetrahydro-beta-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. J Med Chem 2011; 54: 495-509.
20. Tinsley HN, Gary BD, Thaiparambil J, Li N, Lu W, Li Y, Maxuitenko YY, Keeton AB and Piazza GA. Colon tumor cell growth-inhibitory activity of sulindac sulfide and other nonsteroidal antiinflammatory drugs is associated with phosphodiesterase 5 inhibition. Cancer Prev Res (Phila) 2010; 3: 1303-1313.
21. Abadi AH, Gary BD, Tinsley HN, Piazza GA and Abdel-Halim M. Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. Eur J Med Chem 2010; 45: 1278-1286.
22. Shi Z, Jain S, Kim IW, Peng XX, Abraham I, Youssef DT, Fu LW, El Sayed K, Ambudkar SV and Chen ZS. Sipholenol A, a marine-derived sipholane triterpene, potently reverses P-glycoprotein (ABCB1)-mediated multidrug resistance in cancer cells. Cancer Sci 2007; 98: 1373-1380.
23. Shi Z, Tiwari AK, Shukla S, Robey RW, Kim IW, Parmar S, Bates SE, Si QS, Goldblatt CS, Abraham I, Fu LW, Ambudkar SV and Chen ZS. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 2009; 77: 781-793.
24. Li J, Ouyang Y, Zhang X, Zhou W, Wang F, Huang Z, Wang X, Chen Y, Zhang H and Fu L. Effect of HM910, a novel camptothecin derivative, on the inhibition of multiple myeloma cell growth in vitro and in vivo. Am J Cancer Res 2015; 5: 1000-1016.
25. Qiao D, Tang S, Aslam S, Ahmad M, To KK, Wang F, Huang Z, Cai J and Fu L. UMMS-4 enhanced sensitivity of chemotherapeutic agents to ABCB1-overexpressing cells via inhibiting function of ABCB1 transporter. Am J Cancer Res 2014; 4: 148-160.
26. Shi Z, Park HR, Du Y, Li Z, Cheng K, Sun SY, Fu H and Khuri FR. Cables1 complex couples survival signaling to the cell death machinery. Cancer Res 2015; 75: 147-158.
27. Shi Z, Li Z, Li ZJ, Cheng K, Du Y, Fu H and Khuri FR. Cables1 controls p21/Cip1 protein stability by antagonizing proteasome subunit alpha type 3. Oncogene 2015; 34: 2538-2545.
28. Chen XX, Xie FF, Zhu XJ, Lin F, Pan SS, Gong LH, Qiu JG, Zhang WJ, Jiang QW, Mei XL, Xue YQ, Qin WM, Shi Z and Yan XJ. Cyclin-dependent kinase inhibitor dinaciclib potently synergizes with cisplatin in preclinical models of ovarian cancer. Oncotarget 2015; 6: 14926-39.
29. Gong LH, Chen XX, Wang H, Jiang QW, Pan SS, Qiu JG, Mei XL, Xue YQ, Qin WM, Zheng FY, Shi Z and Yan XJ. Piperlongumine induces apoptosis and synergizes with cisplatin or paclitaxel in human ovarian cancer cells. Oxid Med Cell Longev 2014; 2014: 906804.
30. Shi Z, Liang YJ, Chen ZS, Wang XH, Ding Y, Chen LM and Fu LW. Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein. Oncol Rep 2007; 17: 969-976.
31. Shi Z, Parmar S, Peng XX, Shen T, Robey RW, Bates SE, Fu LW, Shao Y, Chen YM, Zang F and Chen ZS. The epidermal growth factor tyrosine kinase inhibitor AG1478 and erlotinib reverse ABCG2-mediated drug resistance. Oncol Rep 2009; 21: 483-489.
32. Qiu JG, Zhang YJ, Li Y, Zhao JM, Zhang WJ, Jiang QW, Mei XL, Xue YQ, Qin WM, Yang Y, Zheng DW, Chen Y, Wei MN and Shi Z. Trametinib modulates cancer multidrug resistance by targeting ABCB1 transporter. Oncotarget 2015; 6: 15494-509.
33. Shi Z, Liang YJ, Chen ZS, Wang XW, Wang XH, Ding Y, Chen LM, Yang XP and Fu LW. Reversal of MDR1/P-glycoprotein-mediated multidrug resistance by vector-based RNA interference in vitro and in vivo. Cancer Biol Ther 2006; 5: 39-47.
34. Laurent A, Nicco C, Chereau C, Goulvestre C, Alexandre J, Alves A, Levy E, Goldwasser F, Panis Y, Soubrane O, Weill B and Batteux F. Controlling tumor growth by modulating endogenous production of reactive oxygen species. Cancer Res 2005; 65: 948-956.
35. Reffelmann T and Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 2003; 108: 239-244.
36. Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, Dolcetti L, Bronte V and Borrello I. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203: 2691-2702.
37. Black KL, Yin D, Ong JM, Hu J, Konda BM, Wang X, Ko MK, Bayan JA, Sacapano MR, Espinoza A, Irvin DK and Shu Y. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008; 1230: 290-302.
38. Di X, Gennings C, Bear HD, Graham LJ, Sheth CM, White KL Jr, Gewirtz DA. Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells. Breast Cancer Res Treat 2010; 124: 349-60.
39. Das A, Durrant D, Mitchell C, Mayton E, Hoke NN, Salloum FN, Park MA, Qureshi I, Lee R, Dent P and Kukreja RC. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci U S A 2010; 107: 18202-18207.
40. Booth L, Roberts JL, Cruickshanks N, Conley A, Durrant DE, Das A, Fisher PB, Kukreja RC, Grant S, Poklepovic A and Dent P. Phosphodiesterase 5 inhibitors enhance chemotherapy killing in gastrointestinal/genitourinary cancer cells. Mol Pharmacol 2014; 85: 408-419.
41. Booth L, Roberts JL, Cruickshanks N, Tavallai S, Webb T, Samuel P, Conley A, Binion B, Young HF, Poklepovic A, Spiegel S and Dent P. PDE5 Inhibitors Enhance Celecoxib Killing in Multiple Tumor Types. J Cell Physiol 2015; 230: 1115-1127.
42. Marques JG, Gaspar VM, Markl D, Costa EC, Gallardo E and Correia IJ. Co-delivery of Sildenafil (Viagra(®)) and Crizotinib for synergistic and improved anti-tumoral therapy. Pharm Res 2014; 31: 2516-2528.
43. de Melo-Diogo D, Gaspar VM, Costa EC, Moreira AF, Oppolzer D, Gallardo E and Correia IJ. Combinatorial delivery of Crizotinib-Palbociclib-Sildenafil using TPGS-PLA micelles for improved cancer treatment. Eur J Pharm Biopharm 2014; 88: 718-729.
44. Shi Z, Tiwari AK, Patel AS, Fu LW and Chen ZS. Roles of sildenafil in enhancing drug sensitivity in cancer. Cancer Res 2011; 71: 3735-3738.
45. Jedlitschky G, Burchell B and Keppler D. The multidrug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J Biol Chem 2000; 275: 30069-30074.
46. Shi Z, Tiwari AK, Shukla S, Robey RW, Singh S, Kim IW, Bates SE, Peng X, Abraham I, Ambudkar SV, Talele TT, Fu LW and Chen ZS. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011; 71: 3029-3041.
47. Chen ZS, Lee K and Kruh GD. Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine. J Biol Chem 2001; 276: 33747-33754.
48. Chen JJ, Sun YL, Tiwari AK, Xiao ZJ, Sodani K, Yang DH, Vispute SG, Jiang WQ, Chen SD and Chen ZS. PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter. Cancer Sci 2012; 103: 1531-1537.
49. Lin F, Hoogendijk L, Buil L, Beijnen JH and van Tellingen O. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo. Eur J Cancer 2013; 49: 2059-2064.
50. Hou Y, Gupta N, Schoenlein P, Wong E, Martindale R, Ganapathy V and Browning D. An anti-tumor role for cGMP-dependent protein kinase. Cancer Lett 2006; 240: 60-68.
51. Yamanaka Y, Mammoto T, Kirita T, Mukai M, Mashimo T, Sugimura M, Kishi Y and Nakamura H. Epinephrine inhibits invasion of oral squamous carcinoma cells by modulating intracellular cAMP. Cancer Lett 2002; 176: 143-148.
52. Fallahian F, Karami-Tehrani F, Salami S and Aghaei M. Cyclic GMP induced apoptosis via protein kinase G in oestrogen receptor-positive and -negative breast cancer cell lines. FEBS J 2011; 278: 3360-3369.
53. Li H, Liu L, David ML, Whitehead CM, Chen M, Fetter JR, Sperl GJ, Pamukcu R and Thompson WJ. Pro-apoptotic actions of exisulind and CP461 in SW480 colon tumor cells involve beta-catenin and cyclin D1 down-regulation. Biochem Pharmacol 2002; 64: 1325-1336.